

09/837998

**WEST**Search results  
for Paper # 15

Help

Logout

Interrupt

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Preferences

Cases

**Search Results -**

Terms	Documents
E3L near20 attenua\$	2

**Database:**

US Patents Full-Text Database  
 US Pre-Grant Publication Full-Text Database  
 JPO Abstracts Database  
 EPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

**Search:**

L8

Refine Search

Recall Text

Clear

**Search History**
**DATE: Thursday, April 10, 2003**    [Printable Copy](#)    [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L8</u>	E3L near20 attenua\$	2	<u>L8</u>
<u>L7</u>	E3L near10 attenua\$	2	<u>L7</u>
<u>L6</u>	l3 and vaccinia near10 expression near5 vector\$	3	<u>L6</u>
<u>L5</u>	l3 and expression near5 vector\$	4	<u>L5</u>
<u>L4</u>	L2 and apathogen\$	0	<u>L4</u>
<u>L3</u>	L2 and (reduc\$ or alter\$) near10 pathogen\$	8	<u>L3</u>
<u>L2</u>	L1 and E3L near10 delet\$	14	<u>L2</u>
<u>L1</u>	vaccinia and E3L	46	<u>L1</u>

END OF SEARCH HISTORY

**Search Results - Record(s) 1 through 14 of 14 returned.**

- 
- ☐ 1. 20030013076 . 02 Mar 01. 16 Jan 03. Parapoxvirus vectors. Robinson, Anthony J., et al. 435/5; 435/320.1 435/325 530/351 536/23.5 536/23.7 536/23.72 C12N015/00 C12Q001/70 C07H021/04 C12N015/09 C07K001/00 C07K014/00 C07K017/00 C12N005/00 C12N015/74.
- 
- ☐ 2. 20020187465 . 01 May 02. 12 Dec 02. Viruses for the treatment of cellular proliferative disorders. Coffey, Matthew C., et al. 435/5; 435/235.1 435/91.1 536/23.72 C12Q001/70 C07H021/04 C12P019/34 C12N007/00 C12N007/01.
- 
- ☐ 3. 20020155529 . 19 Apr 01. 24 Oct 02. Viral vectors having reduced virulence. Jacobs, Bertram, et al. 435/69.1; 435/320.1 435/456 C12P021/02 C12N015/86.
- 
- ☐ 4. 20020110565 . 22 Jun 01. 15 Aug 02. Viral vectors having enhanced effectiveness with reduced virulence. Jacobs, Bertram, et al. 424/199.1; 424/232.1 424/93.2 435/235.1 435/320.1 435/456 A61K048/00 A61K039/12 C12N015/86 C12N007/00 A01N063/00 A61K039/275 A61K039/285 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
- 
- ☐ 5. 20020061298 . 15 Nov 01. 23 May 02. Method for optimally delivering virus to a solid tumor mass. Coffey, Matthew C., et al. 424/93.21; 435/235.1 A61K048/00 C12N007/01.
- 
- ☐ 6. 20020028195 . 28 Sep 01. 07 Mar 02. Viruses for the treatment of cellular proliferative disorders. Coffey, Matthew C., et al. 424/93.21; 424/131.1 424/231.1 424/464 435/235.1 514/9 536/23.72 A61K048/00 A61K039/395 A61K038/13 C07H021/04 A01N063/00 C12N007/00.
- 
- ☐ 7. 20010048919 . 03 May 01. 06 Dec 01. Virus clearance of neoplastic cells from mixed cellular compositions. Morris, Donald, et al. 424/93.21; 435/372 435/456 A61K048/00 C12N005/08 C12N015/86.
- 
- ☐ 8. 6372455 . 19 Apr 01; 16 Apr 02. Recombinant vaccinia viral vectors. Jacobs; Bertram, et al. 435/69.1; 435/320.1 435/5 536/23.72. C12P021/06 C12Q001/70 C12N015/00 C07H021/04.
- 
- ☐ 9. 6130066 . 15 May 98; 10 Oct 00. Vectors having enhanced expression and methods of making and uses thereof. Tartaglia; James, et al. 435/69.1; 435/320.1 435/91.41 536/23.72. C12P021/06.
- 
- ☐ 10. 6004777 . 12 Mar 97; 21 Dec 99. Vectors having enhanced expression, and methods of making and uses thereof. Tartaglia; James, et al. 435/69.1; 435/320.1 435/91.41 536/23.1 536/23.72. C12P021/00 C12N015/63 C12N015/66 C12N015/11.
- 
- ☐ 11. 5990388 . 07 Jun 95; 23 Nov 99. Resistance to viruses and viroids in transgenic plants and animals expressing dsRNA-binding protein. Roth; Don Allen, et al. 800/301; 435/320.1 800/280 800/317.2 800/317.3. C12N005/00 C12N015/00 A01H001/04.
- 
- ☐ 12. 5990091 . 12 Mar 97; 23 Nov 99. Vectors having enhanced expression, and methods of making and uses thereof. Tartaglia; James, et al. 514/44; 424/93.2 435/320.1 435/69.1 435/91.4 435/91.41. C12N015/67 C12N015/86 A61K048/00.
- 
- ☐ 13. WO 200073487 A1 US 20020110565 A1 . Vaccinia virus with amino acids deleted from the E3L gene product, which reduces virulence and improves efficacy, useful as a vaccine. BRANDT, T A, et al. A01N063/00 A61K039/12 A61K039/275 A61K039/285 A61K048/00 C07H021/02 C07H021/04
-

C12N007/00 C12N007/01 C12N015/00 C12N015/09 C12N015/39 C12N015/63 C12N015/64  
C12N015/70 C12N015/74 C12N015/86 C12P021/06.

---

☐ 14. WO 9955910 A1 . Inducing apoptosis in a target cell useful for treating cancer. JACOBS, B  
L. A61K048/00 C07H021/02 C07H021/04 C12N015/85 C12N015/86 C12Q001/68.

---

Generate Collection

Print

Terms	Documents
L1 and E3L near10 delet\$	14

[Previous Page](#)

[Next Page](#)

```
-----  
? set hi ;set hi  
HIGHLIGHT set on as ''  
HIGHLIGHT set on as ''  
? begin 5,6,55,154,155,156,312,399,biotech,biosci  
>>> 135 is unauthorized
```

Set	Items	Description
? s	E3L (10n)	attenuat?
	500	E3L
	772815	ATTENUAT?
	S1	1 E3L (10N) ATTENUAT?

? d s1/9/1  
 Display 1/9/1 (Item 1 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2003 American Chemical Society. All rts. reserv.

130033656 CA: 130(4)33656z JOURNAL  
 Analysis of genomic rearrangement and subsequent gene deletion of the  
 attenuated Orf virus strain D1701  
 AUTHOR(S): Cottone, Rosita; Buttner, Mathias; Bauer, Berthilde; Henkel,  
 Marco; Hettich, Eduard; Rziha, Hanns-Joachim  
 LOCATION: Federal Research Centre for Virus Diseases of Animals,  
 Institute For Vaccines, Tubingen, Germany, D-72076  
 JOURNAL: Virus Res. DATE: 1998 VOLUME: 56 NUMBER: 1 PAGES: 53-67  
 CODEN: VIREDF ISSN: 0168-1702 PUBLISHER ITEM IDENTIFIER:  
 0168-1702(98)00056-2 LANGUAGE: English PUBLISHER: Elsevier Science B.V.  
 SECTION:  
 CA203003 Biochemical Genetics  
 CA206XXX General Biochemistry  
 CA210XXX MICROBIAL, ALGAL, AND FUNGAL BIOCHEMISTRY  
 IDENTIFIERS: Orf virus deletion rearrangement attenuation E2L  
 DESCRIPTORS:

-more-

?  
 Display 1/9/1 (Item 1 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2003 American Chemical Society. All rts. reserv.  
 Deletion(mutation)... DNA sequences... Orf virus... Protein sequences...  
 Rearrangement(genetic)...  
 anal. of genomic rearrangement and subsequent gene deletion of  
 attenuated Orf virus strain D1701  
 Genes(microbial)...  
 early, E3L; anal. of genomic rearrangement and subsequent gene deletion  
 of attenuated Orf virus strain D1701  
 Genes(microbial)...  
 E2L; nonessential for virus replication; anal. of genomic rearrangement  
 and subsequent gene deletion of attenuated Orf virus strain D1701  
 Proteins(specific proteins and subclasses)...  
 gene E3L; anal. of genomic rearrangement and subsequent gene deletion  
 of attenuated Orf virus strain D1701  
 Proteins(specific proteins and subclasses)...  
 gene G1L; anal. of genomic rearrangement and subsequent gene deletion  
 of attenuated Orf virus strain D1701  
 Duplication(mutation)...

-more-

?  
 Display 1/9/1 (Item 1 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2003 American Chemical Society. All rts. reserv.  
 genomic ends of D1701 are duplicated; anal. of genomic rearrangement  
 and subsequent gene deletion of attenuated Orf virus strain D1701  
 Transcription(genetic)...  
 G1L and E3L genes transcribed in D1701; anal. of genomic rearrangement  
 and subsequent gene deletion of attenuated Orf virus strain D1701  
 Genes(microbial)...

G1L; anal. of genomic rearrangement and subsequent gene deletion of  
attenuated Orf virus strain D1701  
Inverted repeat(DNA)...  
terminal; anal. of genomic rearrangement and subsequent gene deletion  
of attenuated Orf virus strain D1701  
CAS REGISTRY NUMBERS:  
216438-88-9 216500-08-2 amino acid sequence; anal. of genomic  
rearrangement and subsequent gene deletion of attenuated Orf virus  
strain D1701  
206685-20-3 nucleotide sequence; anal. of genomic rearrangement and  
subsequent gene deletion of attenuated Orf virus strain D1701

- end of display -

?  
>>>Page beyond end of display invalid  
? s E3L and (apathogen? or vaccine? or attenuat?  
>>>Unmatched parentheses  
? s E3L and (vaccine? or apathogen? or attenuat?)  
Processing  
Processed 10 of 34 files ...  
Completed processing all files  
500 E3L  
650922 VACCINE?  
2269 APATHOGEN?  
772815 ATTENUAT?  
S2 57 E3L AND (VACCINE? OR APATHOGEN? OR ATTENUAT?)  
? rd s2  
...examined 50 records (50)  
...completed examining records  
S3 25 RD S2 (unique items)  
? d s3/3/1-25  
Display 3/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

13512650 BIOSIS NO.: 200200141471  
Expression of vaccinia **E3L** and K3L genes by a novel recombinant  
canarypox HIV **vaccine** vector enhances HIV-1 pseudovirion production  
and inhibits apoptosis in human cells.  
AUTHOR: Fang Zhi-Yu; Limbach Keith; Tartaglia James; Hammonds Jason; Chen  
Xuemin; Spearman Paul(a)  
AUTHOR ADDRESS: (a)Pediatric Infectious Diseases, Vanderbilt University  
School of Medicine, D-7235 MCN, Nashville, TN, 37232-2581\*\*USA E-Mail:  
paul.spearman@mcmail.vanderbilt.edu  
JOURNAL: Virology 291 (2):p272-284 December 20, 2001  
MEDIUM: print  
ISSN: 0042-6822  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

- end of record -

?  
Display 3/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.  
13024732 BIOSIS NO.: 200100231881  
Vectors having enhanced expression and methods of making and uses thereof.  
AUTHOR: Tartaglia James; Cox William I; Gettig Russell Robert; Martinez  
Hector(a); Paoletti Enzo; Pincus Steven E  
AUTHOR ADDRESS: (a)Menands, NY\*\*USA  
JOURNAL: Official Gazette of the United States Patent and Trademark Office

Patents 1239 (2):pNo Pagination Oct. 10, 2000  
MEDIUM: e-file  
ISSN: 0098-1133  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

- end of record -

? d s3/9/1-24

Display 3/9/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13512650 BIOSIS NO.: 200200141471

Expression of vaccinia **E3L** and K3L genes by a novel recombinant  
canarypox HIV **vaccine** vector enhances HIV-1 pseudovirion production  
and inhibits apoptosis in human cells.

AUTHOR: Fang Zhi-Yu; Limbach Keith; Tartaglia James; Hammonds Jason; Chen  
Xuemin; Spearman Paul(a)

AUTHOR ADDRESS: (a)Pediatric Infectious Diseases, Vanderbilt University  
School of Medicine, D-7235 MCN, Nashville, TN, 37232-2581\*\*USA E-Mail:  
paul.spearman@mcmail.vanderbilt.edu

JOURNAL: Virology 291 (2):p272-284 December 20, 2001

MEDIUM: print

ISSN: 0042-6822

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

-more-

?

Display 3/9/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

ABSTRACT: Poxviruses that are **attenuated** for growth in human cells  
provide a safe means of HIV antigen expression and are capable of  
eliciting HIV-specific immune responses, including CD8+ cytotoxic  
T-lymphocyte (CTL) responses. HIV-1 antigen expression in human cells by  
**attenuated** poxvirus vectors may be limited by interferon-mediated  
host defense mechanisms. To enhance HIV antigen expression in human  
cells, the vaccinia virus **E3L** and K3L genes were inserted into a  
canarypox vector that expresses HIV-1 Gag, Env, and a Nef/Pol polyepitope  
string. **E3L** and K3L markedly reduced the activation of the  
double-stranded RNA-dependent protein kinase, PKR, and led to a  
significant reduction in apoptosis in HeLa cells. Production and release  
of HIV-1 antigen in the form of pseudovirions was enhanced in both  
duration and magnitude by this vector modification. The addition of  
immunomodulatory genes to **attenuated** poxviruses represents a novel  
strategy for enhancing antigen production by live vector HIV  
**vaccine** candidates.

-more-

?

Display 3/9/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

DESCRIPTORS:

MAJOR CONCEPTS: Cell Biology; Molecular Genetics (Biochemistry and  
Molecular Biophysics)

BIOSYSTEMATIC NAMES: Galliformes--Aves, Vertebrata, Chordata, Animalia;  
Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia;  
Poxviridae--Animal Viruses, Viruses, Microorganisms; Retroviridae--  
Animal Viruses, Viruses, Microorganisms

ORGANISMS: HIV-1 (Retroviridae); HeLa cell line (Hominidae)--host, human  
cervical carcinoma cells; canarypox (Poxviridae)--gene vector;  
chicken (Galliformes)--host; vaccinia virus (Poxviridae)  
ORGANISMS: PARTS ETC: cytotoxic T-lymphocyte--blood and lymphatics,  
immune system  
BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animal Viruses; Animals; Birds  
; Chordates; Humans; Mammals; Microorganisms; Nonhuman Vertebrates;  
Primates; Vertebrates; Viruses  
CHEMICALS & BIOCHEMICALS: Env protein; Gag protein; HIV antigen--  
expression; HIV **vaccine**--immunologic-drug, immunostimulant-drug

-more-

?

Display 3/9/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.  
GENE NAME: vaccinia virus **E3L** gene (Poxviridae); vaccinia virus K3L  
gene (Poxviridae)  
MISCELLANEOUS TERMS: apoptosis; pseudovirion production  
CONCEPT CODES:  
02502 Cytology and Cytochemistry-General  
02506 Cytology and Cytochemistry-Animal  
02508 Cytology and Cytochemistry-Human  
03502 Genetics and Cytogenetics-General  
03506 Genetics and Cytogenetics-Animal  
03508 Genetics and Cytogenetics-Human  
12512 Pathology, General and Miscellaneous-Therapy (1971- )  
15002 Blood, Blood-Forming Organs and Body Fluids-Blood and Lymph  
Studies  
15004 Blood, Blood-Forming Organs and Body Fluids-Blood Cell Studies  
22005 Pharmacology-Clinical Pharmacology (1972- )  
22018 Pharmacology-Immunological Processes and Allergy  
31500 Genetics of Bacteria and Viruses

-more-

?

Display 3/9/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.  
33506 Virology-Animal Host Viruses  
34502 Immunology and Immunochemistry-General; Methods  
BIOSYSTEMATIC CODES:  
02621 Poxviridae (1993- )  
02623 Retroviridae (1993- )  
85536 Galliformes  
86215 Hominidae

- end of record -

?

Display 3/9/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.  
13024732 BIOSIS NO.: 200100231881  
Vectors having enhanced expression and methods of making and uses thereof.  
AUTHOR: Tartaglia James; Cox William I; Gettig Russell Robert; Martinez  
Hector(a); Paoletti Enzo; Pincus Steven E  
AUTHOR ADDRESS: (a)Menands, NY\*\*USA  
JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1239 (2):pNo Pagination Oct. 10, 2000  
MEDIUM: e-file  
PATENT NUMBER: US 6130066 PATENT DATE GRANTED: October 10, 2000 20001010  
PATENT ASSIGNEE: Virogenetics Corporation PATENT COUNTRY: USA



ISSN: 0098-1133  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Disclosed and claimed are vectors having enhanced expression and

-more-

?

Display 3/9/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid molecule encodes a transcription factor or a translation factor or a transcription factor and a translation factor. The contemporaneous expression can be from operably linking the first and second nucleic molecules to a single promoter, or from operably linking the first nucleic acid molecule to a first promoter and the second nucleic molecule to a second promoter wherein the first and second promoters function substantially contemporaneously. Thus, the first and second nucleic acid molecules can be at the same locus in the vector, or at different loci. The second nucleic acid molecule can encode: one transcription factor or more than one transcription factor; or one translation factor or more than one translation factor; or at least one transcription factor and at least one translation factor. The transcription factor can be from vaccinia H4L, D6, A7, G8R, A1L, A2L, H5R, or combinations thereof. The translation factor can be from a K3L

-more-

?

Display 3/9/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

open reading frame, an **E3L** open reading frame, a VAI RNA, an EBER RNA, a sigma 3 open reading frame, a TRBP open reading frame, or combinations thereof. The vector can be a poxvirus such as an **attenuated** poxvirus, e.g., NYVAC, or ALVAC.

DESCRIPTORS:

MAJOR CONCEPTS: Molecular Genetics (Biochemistry and Molecular Biophysics); Chemistry

BIOSYSTEMATIC NAMES: Poxviridae--Animal Viruses, Viruses, Microorganisms

ORGANISMS: poxvirus (Poxviridae)--genetically modified

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animal Viruses; Microorganisms ; Viruses

MISCELLANEOUS TERMS: gene vector

BIOSYSTEMATIC CODES:

02621 Poxviridae (1993- )

- end of record -

?

Display 3/9/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

12874604 BIOSIS NO.: 200100081753

Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, **E3L**, are required for pathogenesis in a mouse model.

AUTHOR: Brandt Teresa A; Jacobs Bertram L(a)

AUTHOR ADDRESS: (a)Department of Microbiology, Graduate Program in

Molecular and Cellular Biology, Arizona State University, Tempe, AZ,  
85287-2701: bjacobs@asu.edu\*\*USA  
JOURNAL: Journal of Virology 75 (2):p850-856 January, 2001  
MEDIUM: print  
ISSN: 0022-538X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

-more-

?

Display 3/9/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.  
ABSTRACT: The vaccinia virus (VV) **E3L** gene is responsible for providing interferon (IFN) resistance and a broad host range to VV in cell culture. The **E3L** gene product contains two distinct domains. A conserved carboxy-terminal domain, which is required for the IFN resistance and broad host range of the virus, has been shown to bind double-stranded RNA (dsRNA) and inhibit the antiviral dsRNA-dependent protein kinase, PKR. The amino-terminal domain, while conserved among orthopoxviruses, is dispensable in cell culture. To study the role of **E3L** in whole-animal infections, WR strain VV recombinants either lacking **E3L** (VVDeltaE3L) or expressing an amino-terminal (VVE3LDelta83N) or carboxy-terminal (VVE3LDelta26C) truncation of **E3L** were constructed. Whereas wild-type VV had a 50% lethal dose of approximately 104 PFU after intranasal infection, and elicited severe weight loss and morbidity, VVDeltaE3L was **apathogenic**, leading to no death, weight loss, or morbidity. VVDeltaE3L was also **apathogenic** after intracranial injection. Although the amino-terminal domain of **E3L** is dispensable for infection of cells

-more-

?

Display 3/9/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.  
in culture, both the amino- and carboxy-terminal domains of **E3L** were required for full pathogenesis in intranasal infections. These results demonstrate that the entire **E3L** gene is required for pathogenesis in the mouse model.

#### DESCRIPTORS:

MAJOR CONCEPTS: Molecular Genetics (Biochemistry and Molecular Biophysics); Infection  
BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia; Poxviridae--Animal Viruses, Viruses, Microorganisms  
ORGANISMS: mouse (Muridae)--animal model, host; vaccinia virus (Poxviridae)--pathogen  
BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animal Viruses; Animals; Chordates; Mammals; Microorganisms; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates; Viruses  
DISEASES: vaccinia virus infection--viral disease  
CHEMICALS & BIOCHEMICALS: PKR--antiviral double-stranded RNA-dependent

-more-

?

Display 3/9/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.  
protein kinase; double-stranded RNA; interferon  
GENE NAME: mouse **E3L** gene (Muridae)--amino-terminal domains,

carboxy terminal domains, interferon resistance gene  
MISCELLANEOUS TERMS: pathogenesis  
CONCEPT CODES:

36006 Medical and Clinical Microbiology-Virology  
03502 Genetics and Cytogenetics-General  
03506 Genetics and Cytogenetics-Animal  
10062 Biochemical Studies-Nucleic Acids, Purines and Pyrimidines  
10064 Biochemical Studies-Proteins, Peptides and Amino Acids  
31500 Genetics of Bacteria and Viruses  
33506 Virology-Animal Host Viruses

BIOSYSTEMATIC CODES:

02621 Poxviridae (1993- )  
86375 Muridae

- end of record -

?

Display 3/9/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

11697345 BIOSIS NO.: 199800479076

Analysis of genomic rearrangement and subsequent gene deletion of the  
**attenuated** Orf virus strain D1701.

AUTHOR: Cottone Rosita; Buettner Mathias; Bauer Berthilde; Henkel Marco;  
Hettich Eduard; Rziha Hanns-Joachim(a)

AUTHOR ADDRESS: (a)Federal Res. Cent. Virus Dis. Anim., Inst. Vaccines,  
Paul-Ehrlich-Str. 28, D-72076 Tuebingen\*\*Germany

JOURNAL: Virus Research 56 (1):p53-67 July, 1998

ISSN: 0168-1702

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The orf virus (OV) strain D1701 belongs to the genetically  
heterogenous parapoxvirus (PPV) genus of the family Poxviridae. The  
**attenuated** OV D1701 has been licensed as a live **vaccine**

-more-

?

Display 3/9/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

against contagious ecthyma in sheep. Detailed knowledge on the genetic  
structure and organization of this PPV **vaccine** strain is an  
important prerequisite to reveal possible genetic mechanisms of PPV  
**attenuation**. The present study demonstrates a genomic map of the  
approximately 158 kbp DNA of OV D1701 established by hybridization  
studies of cloned restriction fragments covering the complete viral  
genome. The results show an enlargement of the inverted terminal repeats  
(ITR) to up to 18 kbp due to recombination between nonhomologous  
sequences during cell culture adaptation. DNA sequencing of the region  
adjacent to the ITR junction revealed the absence of one open reading  
frame designated E2L. In contrast to a transposition-deletion variant of  
the New Zealand OV strain NZ2 (Fleming et al., 1995) the two genes  
**E3L** (a homologue of dUTPase) and GIL neighboring E2L are retained  
in OV D1701. DNA and RNA analyses proved the presence of E2L gene in  
wild-type OV isolated directly from scab material. The data presented  
indicate that the E2L gene is nonessential for virus replication in vitro  
and in vivo, and may represent one important viral gene in determining

-more-

?

Display 3/9/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.  
virulence and pathogenesis of OV.

DESCRIPTORS:

MAJOR CONCEPTS: Molecular Genetics (Biochemistry and Molecular  
Biophysics); Virology  
BIOSYSTEMATIC NAMES: Poxviridae--Animal Viruses, Viruses, Microorganisms  
ORGANISMS: Orf virus (Poxviridae)--strain-D1701  
BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animal Viruses; Microorganisms  
; Viruses  
CHEMICALS & BIOCHEMICALS: E2L gene  
METHODS & EQUIPMENT: genomic mapping--gene mapping method  
MISCELLANEOUS TERMS: amino acid sequence; gene deletion; nucleotide  
sequence; viral genomic rearrangement; viral replication  
CONCEPT CODES:  
31500 Genetics of Bacteria and Viruses  
33506 Virology-Animal Host Viruses  
BIOSYSTEMATIC CODES:

-more-

?

Display 3/9/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.  
02621 Poxviridae (1993- )

- end of record -

?

Display 3/9/5 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

137309607 CA: 137(21)309607p PATENT  
Vaccinia viral vectors having reduced virulence  
INVENTOR(AUTHOR): Jacobs, Bertram; Langland, Jeffrey; Vijaysri, Sangeetha  
LOCATION: USA  
ASSIGNEE: Arizona Board of Regents  
PATENT: U.S. Pat. Appl. Publ. ; US 20020155529 A1 DATE: 20021024  
APPLICATION: US 837998 (20010419)  
PAGES: 8 pp. CODEN: USXXCO LANGUAGE: English CLASS: 435069100;  
C12P-021/02A; C12N-015/86B  
SECTION:  
CA216002 Fermentation and Bioindustrial Chemistry  
CA203XXX Biochemical Genetics  
CA263XXX Pharmaceuticals  
IDENTIFIERS: Vaccinia viral vector reduced virulence gene E3L  
DESCRIPTORS:  
Gene,microbial...

-more-

?

Display 3/9/5 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.  
.DELTA.7C; vaccinia viral vectors having reduced virulence  
Gene,microbial...  
E3L; vaccinia viral vectors having reduced virulence  
Virulence(microbial)...  
hypovirulence; vaccinia viral vectors having reduced virulence  
Vaccinia virus...  
recombinant; vaccinia viral vectors having reduced virulence  
Mutagenesis...

site-directed, deletion; vaccinia viral vectors having reduced virulence  
Antigens... Genetic engineering... Vaccines... Virus vectors...  
vaccinia viral vectors having reduced virulence

- end of record -

?

Display 3/9/6 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

136289954 CA: 136(19)289954y PATENT  
Construction of recombinant vaccinia viral vectors with incorporated orf virus E3L gene and uses as a vaccine  
INVENTOR(AUTHOR): Jacobs, Bertram; Langland, Jeffrey; Vijaysri, Sangeetha  
LOCATION: USA  
ASSIGNEE: Arizona Board of Regents  
PATENT: United States ; US 6372455 B1 DATE: 20020416  
APPLICATION: US 837997 (20010419)  
PAGES: 8 pp. CODEN: USXXAM LANGUAGE: English CLASS: 435069100;  
C12P-021/06A; C12Q-001/70B; C12N-015/00B; C07H-021/04B  
SECTION:  
CA203002 Biochemical Genetics  
CA201XXX Pharmacology  
CA210XXX MICROBIAL, ALGAL, AND FUNGAL BIOCHEMISTRY  
CA215XXX Immunochemistry  
IDENTIFIERS: vaccinia virus E3L gene recombinant vector vaccine orf

-more-

?

Display 3/9/6 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.  
DESCRIPTORS:

Genetic engineering... Orf virus... Vaccinia virus...  
construction of recombinant vaccinia viral vectors with incorporated orf virus E3L gene and uses as a vaccine  
Gene,microbial...  
E3L; construction of recombinant vaccinia viral vectors with incorporated orf virus E3L gene and uses as a vaccine  
Vaccines...  
recombinant WRorfE3L virus as; construction of recombinant vaccinia viral vectors with incorporated orf virus E3L gene and uses as a vaccine  
Virus vectors...  
recombinant WRorfE3L; construction of recombinant vaccinia viral vectors with incorporated orf virus E3L gene and uses as a vaccine  
Genetic element...  
regulatory, controlling expression of orf E3L gene; construction of recombinant vaccinia viral vectors with incorporated orf virus E3L gene

-more-

?

Display 3/9/6 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.  
and uses as a vaccine

Gene,microbial...  
viral non-essential, of vaccinia virus; construction of recombinant vaccinia viral vectors with incorporated orf virus E3L gene and uses as a vaccine  
CAS REGISTRY NUMBERS:  
408378-11-0 408378-12-1 unclaimed nucleotide sequence; construction of

recombinant vaccinia viral vectors with incorporated orf virus E3L gene  
and uses as a vaccine

- end of record -

?

Display 3/9/7 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

135298757 CA: 135(21)298757t PATENT

Screening methods for identifying viral proteins with interferon  
antagonizing functions and potential antiviral agents

INVENTOR(AUTHOR): Basler, Christopher F.; Garcia-Sastre, Adolfo; Palese,  
Peter

LOCATION: USA

ASSIGNEE: Mount Sinai School of Medicine of New York University

PATENT: PCT International ; WO 200177394 A1 DATE: 20011018

APPLICATION: WO 2001US11543 (20010410) \*US PV195465 (20000410)

PAGES: 76 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/70A;

G01N-033/53B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG;  
BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE;  
SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ;  
BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD

-more-

?

Display 3/9/7 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT;  
LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN;  
TD; TG

SECTION:

CA201005 Pharmacology

CA209XXX Biochemical Methods

CA215XXX Immunochemistry

IDENTIFIERS: screening virucide viral protein interferon antagonist,  
vaccine screening viral protein interferon antagonist, NS1 protein gene  
therapy DNA vaccination

DESCRIPTORS:

Interferons...

.beta.; screening methods for identifying viral proteins with  
interferon antagonizing functions and potential antiviral agents

Proteins,specific or class...

E3L; screening methods for identifying viral proteins with interferon  
antagonizing functions and potential antiviral agents

-more-

?

Display 3/9/7 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

Proteins,specific or class...

green fluorescent; screening methods for identifying viral proteins  
with interferon antagonizing functions and potential antiviral agents

Proteins,specific or class...

ICP34.5 (infected-cell protein 34.5), HSV-1; screening methods for  
identifying viral proteins with interferon antagonizing functions and  
potential antiviral agents

Proteins,specific or class...

NS1 (nonstructural, 1); screening methods for identifying viral

proteins with interferon antagonizing functions and potential antiviral agents  
Proteins,specific or class...  
NS2 (nonstructural, 2); screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents  
Antiviral agents... Drug screening... Ebola virus... Human herpesvirus 1...  
Influenza A virus... Influenza B virus... Influenza C virus... Influenza

-more-

?

Display 3/9/7 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.  
virus... Interferons... Morbillivirus... Mutation... Paramyxovirus...  
Pneumovirus... Promoter(genetic element)... Reporter gene... Respiratory syncytial virus... Rhabdoviridae... Vaccinia virus... Virus...  
screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents  
Proteins,specific or class...  
viral; screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents  
Proteins,specific or class...  
VP35; screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents

- end of record -

?

Display 3/9/8 (Item 4 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.  
  
129226634 CA: 129(18)226634d PATENT  
Viral vectors having enhanced expression, and methods of making and uses thereof  
INVENTOR(AUTHOR): Tartaglia, James; Cox, William I.; Gettig, Russell R.; Martinez, Hector; Paoletti, Enzo; Pincus, Steven E.  
LOCATION: USA  
ASSIGNEE: Virogenetics Corp.  
PATENT: PCT International ; WO 9840501 A1 DATE: 19980917  
APPLICATION: WO 98US2669 (19980213) \*US 816155 (19970312)  
PAGES: 102 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/64A; C12N-015/67B; C12N-015/86B; A61K-048/00B DESIGNATED COUNTRIES: AU; CA; JP  
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE  
SECTION:  
CA203002 Biochemical Genetics  
CA210XXX MICROBIAL, ALGAL, AND FUNGAL BIOCHEMISTRY

-more-

?

Display 3/9/8 (Item 4 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.  
CA215XXX Immunochemistry  
CA263XXX Pharmaceuticals  
IDENTIFIERS: vaccinia poxvirus gene expression vector  
DESCRIPTORS:  
Canarypox virus...  
ALVAC deriv. of; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof  
Genes(microbial)...  
All; viral vaccinia and canarypox vectors having enhanced expression,

and methods of making and uses thereof

Genes(microbial)...

A2L; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

Genes(microbial)...

A7; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

Genes(microbial)...

-more-

?

Display 3/9/8 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

D6; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

Genes(microbial)...

EBER; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

Genes(microbial)...

E3L; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

Protein formation factors... Transcription factors...

genes for; viral vaccinia and canarypox vectors having enhanced  
expression, and methods of making and uses thereof

Genes(microbial)...

G8R; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

Genes(microbial)...

H4L; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

-more-

?

Display 3/9/8 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

Genes(microbial)...

H5R; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

Genes(microbial)...

K3L; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

Vaccinia virus...

NYVAC deriv. of; viral vaccinia and canarypox vectors having enhanced  
expression, and methods of making and uses thereof

Genes(microbial)...

TRBP; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

Genes(microbial)...

VAI; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

Virus vectors...

vCP1452 and vCP1433; viral vaccinia and canarypox vectors having

-more-

?

Display 3/9/8 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

enhanced expression, and methods of making and uses thereof

Gene expression... Immunity... Poxviridae... Promoter(genetic element)...

Vaccines...



viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof

- end of record -

?

Display 3/9/9 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

127342646 CA: 127(25)342646s PATENT

Parapoxvirus vectors based on the orf virus and their use in vector vaccines

INVENTOR(AUTHOR): Robinson, Anthony John; Lyttle, David James

LOCATION: N. Z.,

ASSIGNEE: University of Otago; Robinson, Anthony John; Lyttle, David James

PATENT: PCT International ; WO 9737031 A1 DATE: 19971009

APPLICATION: WO 97NZ40 (19970327) \*NZ 286284 (19960329)

PAGES: 72 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/86A; C12N-005/10B; A61K-039/275B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; HU; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;

-more-

?

Display 3/9/9 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

SECTION:

CA203002 Biochemical Genetics

CA201XXX Pharmacology

CA215XXX Immunochemistry

IDENTIFIERS: parapoxvirus vaccine expression vector, orf virus promoter expression vector vaccine

DESCRIPTORS:

Echinococcus granulosus... Haemonchus... Ostertagia... Taenia ovis...

Trichostrongylus...

antigen genes of, in parapoxvirus vaccine vectors; parapoxvirus vectors based on orf virus and their use in vector vaccines

Human immunodeficiency virus...

env gene of, in parapoxvirus vaccine vectors; parapoxvirus vectors based on orf virus and their use in vector vaccines

Promoter(genetic element)...

E1L, of orf virus, expression of foreign genes from; parapoxvirus

-more-

?

Display 3/9/9 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

vectors based on orf virus and their use in vector vaccines

Genes(microbial)...

E3L, as non-essential for orf virus replication; parapoxvirus vectors based on orf virus and their use in vector vaccines

Promoter(genetic element)...

F1L, of orf virus, expression of foreign genes from; parapoxvirus vectors based on orf virus and their use in vector vaccines

Promoter(genetic element)...

F3L, of orf virus, expression of foreign genes from; parapoxvirus

vectors based on orf virus and their use in vector vaccines  
Antigens... Interferon .gamma.... Interleukin 1.beta.... Interleukin 12...  
Interleukin 1... Interleukin 2... Interleukin 4... Interleukin 5...  
Interleukin 6...  
gene for, in parapoxvirus vaccine vectors; parapoxvirus vectors based  
on orf virus and their use in vector vaccines  
Human herpesvirus...  
glycoprotein gene of, in parapoxvirus vectors; parapoxvirus vectors

-more-

?

Display 3/9/9 (Item 5 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.  
based on orf virus and their use in vector vaccines  
Glycoproteins(specific proteins and subclasses)...  
herpes simplex virus gene for, in parapoxvirus vaccine vectors;  
parapoxvirus vectors based on orf virus and their use in vector  
vaccines  
RFLP(restriction fragment length polymorphism)...  
in orf virus genomes; parapoxvirus vectors based on orf virus and their  
use in vector vaccines  
env gene(microbial)...  
in parapoxvirus vaccine vectors; parapoxvirus vectors based on orf  
virus and their use in vector vaccines  
Promoter(genetic element)...  
late, of orf virus; parapoxvirus vectors based on orf virus and their  
use in vector vaccines  
Early promoter(genetic element)... Promoter(genetic element)...  
of orf virus; parapoxvirus vectors based on orf virus and their use in  
vector vaccines

-more-

?

Display 3/9/9 (Item 5 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.  
Orf virus... Parapoxvirus...  
parapoxvirus vectors based on orf virus and their use in vector  
vaccines  
Testis...  
propagation of parapoxvirus vectors in cultured cells of; parapoxvirus  
vectors based on orf virus and their use in vector vaccines  
Plasmid vectors...  
pTvec50lac-1, transfer vector for orf virus; parapoxvirus vectors based  
on orf virus and their use in vector vaccines  
Plasmid vectors...  
pTvec50lac-2, transfer vector for orf virus; parapoxvirus vectors based  
on orf virus and their use in vector vaccines  
Genetic mapping...  
restriction, of orf virus genomes; parapoxvirus vectors based on orf  
virus and their use in vector vaccines  
Vaccines...  
vector; parapoxvirus vectors based on orf virus and their use in vector

-more-

?

Display 3/9/9 (Item 5 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.  
vaccines  
CAS REGISTRY NUMBERS:  
198229-79-7 B1L early promoter of orf virus; parapoxvirus vectors based on

orf virus and their use in vector vaccines  
198229-85-5 B2L late promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-80-0 B3L early promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-89-9 C1R late promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-76-4 E1L early promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-75-3 E2L early promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-74-2 E3L early promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-81-1 F1L late promoter of orf virus; parapoxvirus vectors based on

-more-

?

Display 3/9/9 (Item 5 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.  
orf virus and their use in vector vaccines  
198229-82-2 F2L late promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-83-3 F3R late promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-84-4 F4R late promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-77-5 G1L early promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-78-6 G2L early promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-86-6 HE2L late promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-88-8 HI1L late promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines  
198229-87-7 HI2L late promoter of orf virus; parapoxvirus vectors based on  
orf virus and their use in vector vaccines

-more-

?

Display 3/9/9 (Item 5 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.  
198228-79-4 198228-80-7 198228-81-8 198228-82-9 198228-83-0  
198228-84-1 nucleotide sequence, non-essential region for cloning of  
foreign genes; parapoxvirus vectors based on orf virus and their use in  
vector vaccines

- end of record -

?

Display 3/9/10 (Item 1 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2003 Inst for Sci Info. All rts. reserv.  
  
06338296 Genuine Article#: YK656 Number of References: 42  
Title: Host range and cytopathogenicity of the highly **attenuated** MVA  
strain of vaccinia virus: Propagation and generation of recombinant  
viruses in a nonhuman mammalian cell line  
Author(s): Carroll MW; Moss B (REPRINT)  
Corporate Source: NIAID, VIRAL DIS LAB, NIH/BETHESDA//MD/20892 (REPRINT);  
NIAID, VIRAL DIS LAB, NIH/BETHESDA//MD/20892  
Journal: VIROLOGY, 1997, V238, N2 (NOV 24), P198-211  
ISSN: 0042-6822 Publication date: 19971124

Publisher: ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS, 525 B ST, STE 1900,  
SAN DIEGO, CA 92101-4495  
Language: English Document Type: ARTICLE  
Geographic Location: USA  
Subfile: CC LIFE--Current Contents, Life Sciences  
Journal Subject Category: VIROLOGY  
Abstract: Modified vaccinia virus Ankara (MVA), **attenuated** by over

-more-

?

Display 3/9/10 (Item 1 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2003 Inst for Sci Info. All rts. reserv.

500 passages in primary chick embyro fibroblasts (CEF), is presently being used as a safe expression vector. We compared the host ranges of MVA and the parental Ankara strain in CEF and 15 permanent cell lines. The cells could be grouped into three categories: permissive, semipermissive, and nonpermissive. For MVA, the permissive category consisted of primary CEF, a quail cell line derived from QT6, and the Syrian hamster cell line BHK-21. Only in BHK-21 cells did the Virus